Altimmune Inc ALT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Eli Lilly's stock plunges as investors eye obesity-drug competition
-
Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk
-
Altimmune's stock pops as analysts see obesity-drug partnership potential
-
Altimmune's stock soars more than 40% after biopharma company says trial of obesity drug led to weight loss
-
Altimmune Gets FDA Fast-Track Designation for Pemvidutide in NASH
Trading Information
- Previous Close Price
- $6.15
- Day Range
- $6.11–6.30
- 52-Week Range
- $2.09–14.84
- Bid/Ask
- $6.19 / $6.28
- Market Cap
- $442.77 Mil
- Volume/Avg
- 1.2 Mil / 2.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 966.79
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company’s pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 59
- Website
- https://www.altimmune.com
Comparables
Valuation
|
Metric
|
ALT
|
TERN
|
EWTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.90 | 2.66 | 5.21 |
Price/Sales | 966.79 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ALT
TERN
EWTX
Financial Strength
|
Metric
|
ALT
|
TERN
|
EWTX
|
|---|---|---|---|
Quick Ratio | 11.08 | 20.57 | 29.79 |
Current Ratio | 11.30 | 21.02 | 30.24 |
Interest Coverage | −3,325.94 | — | — |
Quick Ratio
ALT
TERN
EWTX
Profitability
|
Metric
|
ALT
|
TERN
|
EWTX
|
|---|---|---|---|
Return on Assets (Normalized) | −41.06% | −28.87% | −23.23% |
Return on Equity (Normalized) | −45.20% | −30.36% | −24.43% |
Return on Invested Capital (Normalized) | −49.94% | −34.37% | −29.19% |
Return on Assets
ALT
TERN
EWTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Lgszqbdzt | Lkn | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Vwfqflmd | Vgmrp | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hzfdvgcc | Qjjyxtv | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Stzvgqykz | Vwtjcg | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Scwspwsxn | Pkqx | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Dpdpsyl | Kntw | $29.2 Bil | |||
| Moderna Inc
MRNA
| Fmgnyldx | Ysvp | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Ppzrxxg | Kxks | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lvbhzdtlm | Swdqpk | $13.2 Bil | |||
| Incyte Corp
INCY
| Qqjnmzkz | Xlywkl | $13.0 Bil |
United States